LIFEVANTAGE CORP Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31)
LIFEVANTAGE CORP (LFVN) reported Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) of $133.83 thousand for the 12-month period ending 2012-06-30, per its 10-K filed 2012-09-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionExpense · last filed 2012-11-08
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $1.15K, a 97.31% decline year-over-year.
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for the quarter ending 2011-12-31 was $28.68K, a 2867800.00% increase year-over-year.
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for the quarter ending 2011-09-30 was $104.00K, a 251.39% increase year-over-year.
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for fiscal 2012 was $133.83K, a 38.81% increase from fiscal 2011.
- LIFEVANTAGE CORP share-based goods and nonemployee services transaction, expense (deprecated 2013-01-31) for fiscal 2011 was $96.41K.
| Period end | Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) 3 month | Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) 3 month as first filed | Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) 6 month | Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) 9 month | Share-based Goods and Nonemployee Services Transaction, Expense (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|---|
| 2012-06-30 | $1.15K derived: 10-K 12 month − 10-Q 9 month · filed 2012-09-10 | $1.15K derived: sum of 2 quarters · filed 2012-09-10 | $29.83K derived: sum of 3 quarters · filed 2012-09-10 | $133.83K 10-K · filed 2012-09-10 | |
| 2012-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $28.68K derived: sum of 2 quarters · filed 2012-05-15 | $132.68K 10-Q · filed 2012-05-15 | $175.49K derived: sum of 4 quarters · filed 2012-11-08 | |
| 2011-12-31 | $28.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | $132.68K 10-Q · filed 2012-02-14 | $175.49K derived: sum of 3 quarters · filed 2012-11-08 | $199.49K derived: sum of 4 quarters · filed 2012-11-08 | |
| 2011-09-30 | $104.00K 10-Q · filed 2012-11-08 | $104.45K 10-Q · filed 2011-11-14 | $146.81K derived: sum of 2 quarters · filed 2012-11-08 | $170.81K derived: sum of 3 quarters · filed 2012-11-08 | $170.81K derived: sum of 4 quarters · filed 2012-11-08 |
| 2011-06-30 | $42.81K derived: 10-K 12 month − 10-Q 9 month · filed 2012-09-10 | $66.81K derived: sum of 2 quarters · filed 2012-09-10 | $66.81K derived: sum of 3 quarters · filed 2012-09-10 | $96.41K 10-K · filed 2012-09-10 | |
| 2011-03-31 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $24.00K derived: sum of 2 quarters · filed 2012-05-15 | $53.60K 10-Q · filed 2012-05-15 | ||
| 2010-12-31 | $1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | $29.60K 10-Q · filed 2012-02-14 | |||
| 2010-09-30 | $29.60K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |